TNF and myeloid sarcoma: In experimental models of MS, IFNβ has been shown to reduce tumor necrosis factor alpha (TNF-α) levels, proliferation and activation of T-cell lymphocytes, and pro-inflammatory cytokines produced by T-cells [96].